Details for Patent: 9,139,536

Title:	Anti-infective agents and uses thereof
Abstract:	This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Inventor(s):	Flentge; Charles A. (Salem, WI), Hutchinson; Douglas K. (Antioch, IL), Betebenner; David A. (Libertyville, IL), DeGoey; David A. (Salem, WI), Donner; Pamela L. (Mundelein, IL), Kati; Warren M. (Gurnee, IL), Krueger; Allan C. (Gurnee, IL), Liu; Dachun (Waukegan, IL), Liu; Yaya (Buffalo Grove, IL), Longenecker; Kenton L. (Grayslake, IL), Maring; Clarence J. (Palatine, IL), Motter; Christopher E. (Oak Creek, WI), Pratt; John K. (Kenosha, WI), Randolph; John T. (Libertyville, IL), Rockway; Todd W. (Grayslake, IL), Stewart; Kent D. (Gurnee, IL), Wagner; Rolf (Antioch, IL), Chen; Shuang (Gurnee, IL), Gao; Yi (Vernon Hills, IL), Lou; Xiaochun (Long Grove, IL), Zhang; Geoff G. Z. (Libertyville, IL)
Assignee:	AbbVie Inc. (North Chicago, IL)
Filing Date:	Mar 15, 2013
Application Number:	13/838,223
Claims:	1. A method of treating hepatitis C virus (HCV) infection, comprising administering N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyp- henyl)naphthalen-2-yl)methanesulfonamide, or a pharmaceutically acceptable salt thereof, to a HCV patient in need thereof. 2. The method of claim 1, further comprising administering another HCV inhibitor to said patient. 3. The method of claim 2, wherein said anther HCV inhibitor is a HCV protease inhibitor. 4. The method of claim 1, comprising administering monosodium salt of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyp- henyl)naphthalen-2-yl)methanesulfonamide to said patient. 5. The method of claim 4, further comprising administering another HCV inhibitor to said patient. 6. The method of claim 5, wherein said anther HCV inhibitor is a HCV protease inhibitor.